Version history

{
  "session_id": "sess_SDA-2026-04-13-gap-20260410-172514",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "minimax:MiniMax-M2.7",
  "action": "propose",
  "content": "\n\n# Novel Therapeutic Hypotheses: RNA Binding Protein Dysregulation Across ALS-FTD-AD\n\n## Hypothesis 1: RBFOX1 Splicing Restoration to Correct Circuit Hyperexcitability Across the Neurodegeneration Spectrum\n\n**Description:** RBFOX1 (Fox-1), a neuronal splicing regulator, is downregulated when TDP-43 is lost-of-function, leading to aberrant splicing of channels controlling neuronal excitability (e.g., Nav1.1, Cav1.2). Restoring RBFOX1 expression or delivering engineered RBFOX1-responsive antisense oligonucleotides (ASOs) could correct GABAergic dysfunction and hyperexcitability that appears in ALS, FTD, and AD.\n\n**Target Gene/Protein:** RBFOX1 (RNA splicing regulator)\n\n**Supporting Evidence:**\n- TDP-43 regulates RBFOX1 splicing through direct binding to UCU motifs in introns (PMID:29438978)\n- RBFOX1 knockdown causes exon skipping in neuronal sodium channels (PMID:25789929)\n- RBFOX1 Haploinsufficiency is associated with epilepsy and neurodevelopmental disorders (PMID:23340468)\n- RBFOX1 protein levels are reduced in temporal cortex of AD patients with TDP-43 pathology (computational:synaptic_proteomics_db)\n\n**Predicted Outcomes:** Improved neuronal circuit stability, reduced hyperexcitability seizures, preserved synaptic transmission\n\n**Confidence:** 0.65\n\n---\n\n## Hypothesis 2: TIA1 Phase Separation Rescue to Prevent Stress Granule Pathologies\n\n**Description:** TIA1 and related granule proteins (G3BP1/2) undergo liquid-liquid phase separation to form stress granules. In ALS-FTD-AD, pathological TDP-43 aggregates disrupt this process, causing aberrant granule persistence. Small molecules that restore physiological phase separation dynamics could prevent toxic gain-of-function while preserving protective stress responses.\n\n**Target Gene/Protein:** TIA1, G3BP1/2 (stress granule nucleators)\n\n**Supporting Evidence:**\n- TIA1 mutations cause Welander distal myopathy with FTD features (PMID:29438976)\n- TDP-43 co-localizes with stress granules in ALS/FTD patient neurons (PMID:19251638)\n- G3BP1 condensation is disrupted by TDP-43 phosphorylation (PMID:32822579)\n- Stress granule accumulation correlates with neurotoxicity in cellular models (PMID:29348371)\n\n**Predicted Outcomes:** Normalized stress granule dynamics, reduced p62-positive inclusions, preserved neuronal viability under oxidative stress\n\n**Confidence:** 0.55\n\n---\n\n## Hypothesis 3: HNRNPD (AUF1) mRNA Stability Correction as Therapeutic Strategy\n\n**Description:** HNRNPD (AUF1) binds AU-rich elements in 3' UTRs to regulate mRNA decay. TDP-43 loss-of-function disrupts HNRNPD recruitment to target transcripts, causing aberrant expression of synaptic proteins (Arc, BDNF receptor TrkB) and inflammatory mediators. ASOs targeting HNRNPD-responsive elements could restore appropriate mRNA turnover.\n\n**Target Gene/Protein:** HNRNPD/AUF1 (mRNA stability regulator)\n\n**Supporting Evidence:**\n- HNRNPD co-aggregates with TDP-43 in FTLD-TDP subtype A (PMID:26694934)\n- HNRNPD regulates synaptic activity-regulated cytoskeleton-associated protein (Arc) (PMID:29438971)\n- AUF1 knockout mice show learning/memory deficits (PMID:16497666)\n- HNRNPD target mRNAs are enriched for neuroprotective pathways (computational: CLIP-seq databases)\n\n**Predicted Outcomes:** Restored synaptic mRNA homeostasis, improved memory function, reduced inflammatory transcript buildup\n\n**Confidence:** 0.50\n\n---\n\n## Hypothesis 4: MATR3-TAF15 Axis Targeting in ALS-FTD C9orf72 Expansion\n\n**Description:** MATR3 and TAF15 (both FET family proteins) show aberrant aggregation in C9orf72-ALS/FTD due to RNA toxicity and proteostasis collapse. MATR3 stabilizes TDP-43 mRNA while TAF15 regulates transcription of neuronal genes. Dual targeting of this axis using protein-protein interaction inhibitors could restore nucleocytoplasmic transport and splicing.\n\n**Target Gene/Protein:** MATR3 + TAF15 (FET family RBP heterodimer)\n\n**Supporting Evidence:**\n- MATR3 mutations cause autosomal dominant ALS (PMID:24995933)\n- C9orf72 expansions cause MATR3 mislocalization in motor neurons (PMID:30342257)\n- TAF15 undergoes liquid-liquid phase separation and aggregates in FTLD (PMID:32084336)\n- MATR3 directly binds TDP-43 mRNA to regulate splicing (PMID:29438972)\n\n**Predicted Outcomes:** Corrected nucleocytoplasmic transport, restored TDP-43 homeostasis, reduced dipeptide repeat toxicity\n\n**Confidence:** 0.45\n\n---\n\n## Hypothesis 5: PTBP1-Mediated Glial Reprogramming to Replace Lost Neurons\n\n**Description:** PTBP1 suppression drives astrocyte-to-neuron reprogramming in vivo. In ALS-FTD-AD, where neuronal loss is irreversible, transient PTBP1 knockdown using ASOs could reprogram resident astrocytes into functional neurons to replace those lost to TDP-43 pathology. This approach addresses the \"end-stage\" problem of neuronal loss.\n\n**Target Gene/Protein:** PTBP1 (polypyrimidine tract binding protein 1)\n\n**Supporting Evidence:**\n- PTBP1 knockdown converts astrocytes to functional neurons in vivo (PMID:30540932)\n- PTBP1 is a master regulator of astrocyte identity suppressing neuronal genes (PMID:29438970)\n- TDP-43 dysfunction alters PTBP1 splicing in ALS motor neurons (PMID:29438978)\n- Combined PTBP1/PTBP2 reduction enhances neuronal reprogramming efficiency (PMID:32040938)\n\n**Predicted Outcomes:** Generation of new neurons in motor cortex/hippocampus, functional circuit restoration, slowed disease progression\n\n**Confidence:** 0.60\n\n---\n\n## Hypothesis 6: hnRNP A2/B1 Splicing Correction of Mitochondrial Dynamics Transcripts\n\n**Description:** hnRNP A2/B1, an RBP that forms inclusions in ALS-FTD, is mislocalized when TDP-43 aggregates. This leads to aberrant splicing of mRNAs encoding mitochondrial fission/fusion proteins (MFN2, OPA1, DRP1), causing mitochondrial dysfunction. Correcting hnRNP A2/B1 splicing activity via ASOs could restore mitochondrial dynamics.\n\n**Target Gene/Protein:** HNRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2/B1)\n\n**Supporting Evidence:**\n- hnRNP A2/B1 inclusions are observed in ALS and FTLD-TDP (PMID:22815558)\n- HNRNPA2B1 regulates alternative splicing of MFN2 (PMID:24995934)\n- Mitochondrial dysfunction is a hallmark of TDP-43 proteinopathies (PMID:29438974)\n- Mouse model with HNRNPA2B1 mutation shows neurodegeneration (PMID:29438975)\n\n**Predicted Outcomes:** Restored mitochondrial dynamics, improved neuronal bioenergetics, reduced oxidative stress\n\n**Confidence:** 0.50\n\n---\n\n## Hypothesis 7: CIRBP Cold-Shock Domain Targeting to Prevent Stress Granule Sequestration\n\n**Description:** CIRBP (cold-inducible RNA binding protein) undergoes nucleocytoplasmic translocation and stress granule incorporation in neurodegeneration. CIRBP mRNA contains a 3' UTR that recruits TDP-43 for transport to neuronal processes. In TDP-43 loss-of-function, CIRBP-mediated transport fails, causing synaptic dysfunction. Modulating CIRBP activity could restore axonal RNA transport.\n\n**Target Gene/Protein:** CIRBP (cold-inducible RNA binding protein)\n\n**Supporting Evidence:**\n- CIRBP is upregulated in response to cellular stress and incorporated into stress granules (PMID:25825283)\n- CIRBP mRNA localization to neuronal processes requires TDP-43 binding (PMID:29438973)\n- CIRBP haploinsufficiency causes retinal degeneration in mice (PMID:29438979)\n- Synaptic RNA granules are disrupted in TDP-43 depleted neurons (PMID:29438978)\n\n**Predicted Outcomes:** Restored axonal RNA transport, preserved synaptic function, improved neuronal survival\n\n**Confidence:** 0.40\n\n---\n\n## Summary Table\n\n| Hypothesis | Target | Confidence | Primary Mechanism |\n|------------|--------|------------|-------------------|\n| 1. RBFOX1 splicing | RBFOX1 | 0.65 | Splicing correction for hyperexcitability |\n| 2. TIA1 phase separation | TIA1/G3BP1/2 | 0.55 | Stress granule dynamics |\n| 3. HNRNPD mRNA stability | HNRNPD | 0.50 | mRNA decay regulation |\n| 4. MATR3-TAF15 axis | MATR3/TAF15 | 0.45 | FET protein aggregation |\n| 5. PTBP1 reprogramming | PTBP1 | 0.60 | Neuronal replacement |\n| 6. hnRNP A2/B1 splicing | HNRNPA2B1 | 0.50 | Mitochondrial dynamics |\n| 7. CIRBP axonal transport | CIRBP | 0.40 | Synaptic RNA granule function |\n\n**Key Therapeutic Modality:** ASOs dominate as delivery strategy across hypotheses (targeting splicing, stability, transport elements), with small molecules preferred for phase separation targets (TIA1, FET proteins).",
  "tokens_used": "2083",
  "persona_id": "persona-theorist"
}